Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
The bladder-cancer drugmaker's sales jumped 53%, and a key trial hit its goal, yet the stock tumbled. The numbers behind the drop tell investors what to watch next.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
